Your browser doesn't support javascript.
Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center retrospective cohort study.
Wang, Jing; Lu, Zequn; Jin, Meng; Wang, Ying; Tian, Kunming; Xiao, Jun; Cai, Yimin; Wang, Yanan; Zhang, Xu; Chen, Tao; Yao, Zhi; Yang, Chunguang; Deng, Renli; Zhong, Qiang; Deng, Xiongbo; Chen, Xin; Yang, Xiang-Ping; Wei, Gonghong; Wang, Zhihua; Tian, Jianbo; Chen, Xiao-Ping.
  • Wang J; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Lu Z; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Jin M; Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
  • Wang Y; Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, 430024, China.
  • Tian K; Institute of Reproductive Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Xiao J; School of Nursing, Zunyi Medical University, Zunyi, 563099, China.
  • Cai Y; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Wang Y; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Zhang X; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Chen T; Key Laboratory of Environment and Health, Ministry of Education & Ministry of Environmental Protection, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Yao Z; Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Yang C; Department of Respirology and Tuberculosis Specialty, Wuhan Pulmonary Hospital, Wuhan, 430030, China.
  • Deng R; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Zhong Q; The Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical University, Zhuhai, 519199, China.
  • Deng X; Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Chen X; Department of Radiology, Wuhan Jinyintan Hospital, Wuhan, 430048, China.
  • Yang XP; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Wei G; Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Wang Z; Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, 90014, Finland.
  • Tian J; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. zhwang_hust@hotmail.com.
  • Chen XP; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. tianjb@hust.edu.cn.
Front Med ; 16(1): 111-125, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1356049
ABSTRACT
The Coronavirus disease 2019 (COVID-19) has spread globally. Although mixed liver impairment has been reported in COVID-19 patients, the association of liver injury caused by specific subtype especially chronic hepatitis B (CHB) with COVID-19 has not been elucidated. In this multi-center, retrospective, and observational cohort study, 109 CHB and 327 non-CHB patients with COVID-19 were propensity score matched at an approximate ratio of 31 on the basis of age, sex, and comorbidities. Demographic characteristics, laboratory examinations, disease severity, and clinical outcomes were compared. Furthermore, univariable and multivariable logistic and Cox regression models were used to explore the risk factors for disease severity and mortality, respectively. A higher proportion of CHB patients (30 of 109 (27.52%)) developed into severe status than non-CHB patients (17 of 327 (5.20%)). In addition to previously reported liver impairment markers, such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin, we identified several novel risk factors including elevated lactate dehydrogenase (⩾ 245 U/L, hazard ratio (HR) = 8.639, 95% confidence interval (CI) = 2.528-29.523; P < 0.001) and coagulation-related biomarker D-dimer (⩾ 0.5 µg/mL, HR = 4.321, 95% CI = 1.443-12.939; P = 0.009) and decreased albumin (< 35 g/L, HR = 0.131, 95% CI = 0.048-0.361; P < 0.001) and albumin/globulin ratio (< 1.5, HR = 0.123, 95% CI = 0.017-0.918; P = 0.041). In conclusion, COVID-19 patients with CHB were more likely to develop into severe illness and die. The risk factors that we identified may be helpful for early clinical surveillance of critical progression.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hepatitis B, Chronic / COVID-19 Type of study: Controlled clinical trial / Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Topics: Long Covid Limits: Humans Language: English Journal: Front Med Year: 2022 Document Type: Article Affiliation country: S11684-021-0854-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hepatitis B, Chronic / COVID-19 Type of study: Controlled clinical trial / Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Topics: Long Covid Limits: Humans Language: English Journal: Front Med Year: 2022 Document Type: Article Affiliation country: S11684-021-0854-5